INT57665

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1994
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 35
Total Number 35
Disease Relevance 8.05
Pain Relevance 9.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Cyp2e1) oxidoreductase activity (Cyp2e1) endoplasmic reticulum (Cyp2e1)
enzyme binding (Cyp2e1)
Anatomy Link Frequency
liver 9
hepatocytes 2
DA neurons 1
1A2 1
brain 1
Cyp2e1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Paracetamol 81 99.98 Very High Very High Very High
Dopamine 35 99.76 Very High Very High Very High
Nicotine 5 99.50 Very High Very High Very High
withdrawal 11 99.44 Very High Very High Very High
tetrodotoxin 4 99.04 Very High Very High Very High
isoflurane 4 98.40 Very High Very High Very High
Substantia nigra 32 98.16 Very High Very High Very High
halothane 1 97.56 Very High Very High Very High
adenocard 28 96.36 Very High Very High Very High
tolerance 3 93.40 High High
Disease Link Frequency Relevance Heat
Injury 22 99.82 Very High Very High Very High
Overdose 3 98.72 Very High Very High Very High
Disease 81 98.60 Very High Very High Very High
Brain Injury 25 98.60 Very High Very High Very High
Necrosis 4 98.24 Very High Very High Very High
Hepatotoxicity 42 98.08 Very High Very High Very High
Toxicity 3 96.52 Very High Very High Very High
Appetite Loss 5 96.18 Very High Very High Very High
Obesity 1 92.36 High High
Diabetes Mellitus 1 92.00 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The effect of inhibition of CYP2E1 by phenylethyl isothiocyanate (100 mg/kg) on extracellular DA in the SN was unaltered following pretreatment with gamma-butyrolactone and GBR-12909, drugs that inhibit firing of DA neurons and DA re-uptake, respectively.
Negative_regulation (inhibition) of CYP2E1 in DA neurons associated with dopamine and substantia nigra
1) Confidence 0.59 Published 2008 Journal Synapse Section Abstract Doc Link 18288650 Disease Relevance 0.16 Pain Relevance 0.68
Preadministration of tetrodotoxin or reserpine, however, abolished the effect of CYP2E1 inhibition.
Negative_regulation (inhibition) of CYP2E1 associated with tetrodotoxin
2) Confidence 0.59 Published 2008 Journal Synapse Section Abstract Doc Link 18288650 Disease Relevance 0.13 Pain Relevance 0.77
SAM was a non-competitive inhibitor of CYP2E1 catalytic activity and its inhibitory actions could not be mimicked by methionine, SAH or MTA.
Negative_regulation (inhibitor) of CYP2E1 associated with adenocard
3) Confidence 0.57 Published 2005 Journal Biochem. Pharmacol. Section Abstract Doc Link 15763544 Disease Relevance 0 Pain Relevance 0.16
However, SAM is a weak inhibitor of CYP2E1.
Negative_regulation (inhibitor) of CYP2E1
4) Confidence 0.57 Published 2005 Journal Biochem. Pharmacol. Section Abstract Doc Link 15763544 Disease Relevance 0.09 Pain Relevance 0.11
Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine.
Negative_regulation (Inhibition) of CYP2E1
5) Confidence 0.57 Published 2005 Journal Biochem. Pharmacol. Section Title Doc Link 15763544 Disease Relevance 0 Pain Relevance 0.16
Since the K(i) for SAM inhibition of CYP2E1 activity is relatively high, inhibition of CYP2E1 activity is not likely to play a major role in the ability of SAM to protect against the hepatotoxicity produced by toxins requiring metabolic activation by CYP2E1 such as acetaminophen, ethanol, carbon tetrachloride, thioacetamide and carcinogens.
Negative_regulation (inhibition) of CYP2E1 associated with paracetamol and hepatotoxicity
6) Confidence 0.57 Published 2005 Journal Biochem. Pharmacol. Section Abstract Doc Link 15763544 Disease Relevance 0.09 Pain Relevance 0.13
Since the K(i) for SAM inhibition of CYP2E1 activity is relatively high, inhibition of CYP2E1 activity is not likely to play a major role in the ability of SAM to protect against the hepatotoxicity produced by toxins requiring metabolic activation by CYP2E1 such as acetaminophen, ethanol, carbon tetrachloride, thioacetamide and carcinogens.
Negative_regulation (inhibition) of CYP2E1 associated with paracetamol and hepatotoxicity
7) Confidence 0.57 Published 2005 Journal Biochem. Pharmacol. Section Abstract Doc Link 15763544 Disease Relevance 0.10 Pain Relevance 0.13
In rats, CYP2E has been shown to decrease to control levels after this time period of withdrawal from ethanol.
Negative_regulation (decrease) of CYP2E associated with withdrawal
8) Confidence 0.57 Published 1997 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 9144448 Disease Relevance 0.40 Pain Relevance 0.50
This 11-hr withdrawal from ethanol resulted in a decrease in hepatic levels of ethanol-induced CYP2E; however, considerable induction was still evident.
Negative_regulation (decrease) of CYP2E associated with withdrawal
9) Confidence 0.57 Published 1997 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 9144448 Disease Relevance 0.43 Pain Relevance 0.60
Here, a mixture of ketoconazole, isoniazid and caffeine (inhibitor solution), known inhibitors of CYP3A, CYP2E1 and CYP1A2, was investigated for prevention of hepatotoxicity after paracetamol over-dose in rats.
Negative_regulation (inhibitors) of CYP2E1 associated with paracetamol and hepatotoxicity
10) Confidence 0.54 Published 2004 Journal Hum Exp Toxicol Section Abstract Doc Link 15027815 Disease Relevance 0.41 Pain Relevance 0.57
The rats with protein-calorie malnutrition (PCM, 5% casein diet for a period of 4-week) were reported to exhibit 60 and 80% suppression in the hepatic microsomal cytochrome P450 (CYP) 1A2 and CYP2C11 levels, respectively, and 40-50% decreases in CYP2E1 and CYP3A1/2 levels compared to control (23% casein diet for a period of 4-week) based on Western blot analysis.
Negative_regulation (decreases) of CYP2E1 in 1A2 associated with appetite loss
11) Confidence 0.52 Published 2004 Journal Arch. Pharm. Res. Section Abstract Doc Link 15356995 Disease Relevance 0.17 Pain Relevance 0
The serum AST activities corresponding to a 50% decrease of CYP2C 11, CYP2E1, CYP3A2 and CYP1A2 activities were about 710, 780, 1030 and 1300 IU/l, respectively.
Negative_regulation (decrease) of CYP2E1
12) Confidence 0.51 Published 2004 Journal Int J Pharm Section Abstract Doc Link 14706259 Disease Relevance 0.15 Pain Relevance 0.08
TAO was dissolved in saline instead of dimethylsulfoxide, the solvent most usually employed, since dimethylsulfoxide inhibits CYP2E.
Negative_regulation (inhibits) of CYP2E
13) Confidence 0.50 Published 1997 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 9144448 Disease Relevance 0.45 Pain Relevance 0.55
Such inhibitors of cytochrome P4502E1 as dialyl sulphide, disulfiram have hepatoprotective action.
Negative_regulation (inhibitors) of cytochrome P4502E1
14) Confidence 0.49 Published 2004 Journal Ukr. Biokhim. Zh. Section Abstract Doc Link 16100894 Disease Relevance 0.37 Pain Relevance 0.15
We have previously reported that CYP2E1 inhibition increases extracellular dopamine (DA) in the SN.
Negative_regulation (inhibition) of CYP2E1 associated with dopamine and substantia nigra
15) Confidence 0.43 Published 2008 Journal Synapse Section Abstract Doc Link 18288650 Disease Relevance 0.19 Pain Relevance 0.48
Using the standard induction procedures [Aroclor 1254 or a combination of phenobarbitone (PB) and beta-naphthoflavone (beta-NF)] the level of CYP2E1 in rat liver is actually suppressed and it has been suggested that this may account for the negative findings with these compounds in the Ames test.
Negative_regulation (suppressed) of CYP2E1 in liver
16) Confidence 0.43 Published 1994 Journal Mutagenesis Section Abstract Doc Link 8208127 Disease Relevance 0 Pain Relevance 0.13
Such effects were not observed in cells lacking CYP2E1.
Negative_regulation (lacking) of CYP2E1
17) Confidence 0.43 Published 2004 Journal Biochem. Pharmacol. Section Abstract Doc Link 15242817 Disease Relevance 0 Pain Relevance 0.53
CONCLUSIONS: In non-induced patients, CYP2E1 activity decreases in line with severity of alcoholic liver disease.
Negative_regulation (decreases) of CYP2E1 in liver
18) Confidence 0.43 Published 1997 Journal J. Hepatol. Section Body Doc Link 9453426 Disease Relevance 0.05 Pain Relevance 0
When non-induced patients with alcoholic liver disease were arranged in progressing order of liver damage (minor, more pronounced, severe alcoholic liver disease), there was a significant decline in CYP2E1 activity (p=0.0008).
Negative_regulation (decline) of CYP2E1 in liver
19) Confidence 0.43 Published 1997 Journal J. Hepatol. Section Body Doc Link 9453426 Disease Relevance 0.05 Pain Relevance 0
The aims of the present study were by using in vivo microdialysis in rat, to elucidate the mechanisms responsible for the increase in extracellular DA induced by CYP2E1 inhibition and to explore whether ROS is produced in the SN, both with and without the presence of an exogenous CYP2E1 substrate.
Negative_regulation (inhibition) of CYP2E1 associated with dopamine and substantia nigra
20) Confidence 0.43 Published 2008 Journal Synapse Section Abstract Doc Link 18288650 Disease Relevance 0.17 Pain Relevance 0.64

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox